180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 59.7% in April

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 17,100 shares, a decline of 59.7% from the March 31st total of 42,400 shares. Based on an average trading volume of 103,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 3.3% of the shares of the company are short sold.

Institutional Investors Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Armistice Capital LLC bought a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 131,000 shares of the company’s stock, valued at approximately $80,000. Armistice Capital LLC owned 2.46% of 180 Life Sciences as of its most recent filing with the Securities & Exchange Commission. 4.07% of the stock is owned by institutional investors.

180 Life Sciences Stock Down 2.8 %

Shares of ATNF traded down $0.05 during mid-day trading on Thursday, hitting $1.77. 15,531 shares of the company traded hands, compared to its average volume of 106,529. 180 Life Sciences has a 1 year low of $1.33 and a 1 year high of $27.93. The stock has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $4.69.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.